QRC-PVD Clinical Trial - Metformin Aneurysm Trial (MAT)
- Aboriginals and Torres Strait Islanders in Marine Science
- Courses
- Future Students
- Current Students
- Research and Teaching
- Partners and Community
- About JCU
- Reputation and Experience
- Celebrating 50 Years
- Academy
- Anthropological Laboratory for Tropical Audiovisual Research (ALTAR)
- Anton Breinl Research Centre
- Agriculture Technology and Adoption Centre (AgTAC)
- Living on Campus
- How to apply
- Advanced Analytical Centre
- Alumni
- AMHHEC
- JCU Aquaculture Solutions
- AusAsian Mental Health Research Group
- ARCSTA
- Area 61
- Association of Australian University Secretaries
- Australian Lions Stinger Research
- Australian Tropical Herbarium
- Australian Quantum & Classical Transport Physics Group
- Boating and Diving
- JCU-CSIRO Partnership
- Employability Edge
- Career Ready Plan
- Careers at JCU
- Careers and Employability
- Chancellery
- Centre for Tropical Bioinformatics and Molecular Biology
- CITBA
- CMT
- CASE
- College of Business, Law and Governance
- College of Healthcare Sciences
- College of Medicine and Dentistry
- College of Science and Engineering
- CPHMVS
- Centre for Disaster Solutions
- CSTFA
- Cyber Security Hub
- Cyclone Testing Station
- The Centre for Disaster Studies
- Daintree Rainforest Observatory
- Discover Nature at JCU
- Research Division
- Services and Resources Division
- Education Division
- Elite Athletes
- eResearch
- Environmental Research Complex [ERC]
- Estate
- Fletcherview
- Foundation for Australian Literary Studies
- Gender Equity Action and Research
- General Practice and Rural Medicine
- JC 'U' Orientation
- Give to JCU
- Governance
- Information for JCU Cairns Graduates
- Art of Academic Writing
- Art of Academic Editing
- Graduate Research School
- Graduation
- Indigenous Education and Research Centre
- Indigenous Engagement
- Indigenous Legal Needs Project
- Inherent Requirements
- IsoTropics Geochemistry Lab
- IT Services
- International Schools
- International Students
- Research and Innovation Services
- JCU Eduquarium
- JCU Events
- JCU Global Experience
- JCU Ideas Lab
- JCU Job Ready
- JCU Motorsports
- JCU Prizes
- JCU Sport
- JCU Turtle Health Research
- Language and Culture Research Centre
- CEE
- LearnJCU
- Library
- Mabo Decision: 30 years on
- MARF
- Marine Geophysics Laboratory
- New students
- Off-Campus Students
- Office of the Vice Chancellor and President
- Virtual Open Day
- Orpheus
- Outstanding Alumni
- Parents and Partners
- Pathways to university
- Planning for your future
- Placements
- Policy
- PAHL
- Publications
- Professional Experience Placement
- Queensland Research Centre for Peripheral Vascular Disease
- Rapid Assessment Unit
- RDIM
- Researcher Development Portal
- Safety and Wellbeing
- Scholarships
- Contextual Science for Tropical Coastal Ecosystems
- Staff
- State of the Tropics
- Strategic Procurement
- Student Equity and Wellbeing
- Student profiles
- SWIRLnet
- TARL
- TESS
- TREAD
- TropEco for Staff and Students
- TQ Maths Hub
- TUDLab
- Unicare Centre and Unicampus Kids
- UAV
- VAVS Home
- Work Health and Safety
- WHOCC for Vector-borne & NTDs
- Media
- Copyright and Terms of Use
- Australian Institute of Tropical Health & Medicine
- Clinical Psychedelic Research Lab
An abdominal aortic aneurysm (AAA) is the ballooning of part of the aorta in the abdomen. AAAs vary in size but tend to gradually grow larger. Once they reach a size of 5.5cm in diameter, they have a high chance of rupture. The cause of AAA is not known but there are some risk factors such as history of smoking, age and being male.
Currently, there are no effective drug treatments available for AAA. However, research suggests that a drug called metformin (which is used to lower blood sugar levels in people with type 2 diabetes) may reduce the risk of adverse AAA events such as AAA repair and AAA rupture. A large clinical trial is needed to test this. Metformin is a safe, well-tolerated drug that is suitable for use in a range of populations (including people without diabetes). The main aim of this clinical trial is to test if metformin reduces the risk of adverse AAA events (i.e., AAA repair or rupture).
Recruitment Status | Recruiting |
---|---|
Ethics Approval | Human Research Ethics Approval |
Participants will have an initial Screening Visit to confirm eligibility and review health and medical history. Following successful screening, participants will be randomised to either the active metformin study medication or a placebo and continue taking the study medication for approximately three and a half years. Over this time, participants will be regularly followed up by their study coordinator every three months, over the phone, and annually in person if possible. Participants in MAT will also have their routine imaging (i.e. ultrasounds from their treating hospital) collected, and repeat blood tests on occasion.
Screening |
| 1-2 hours |
---|---|---|
Pre-Randomisation | ||
Week 2 | Phone call check in with study coordinator | 10-15 minutes |
Week 6 | Phone call check in with study coordinator | 10-15 minutes |
Week 6 | Phone call check in with study coordinator | 10-15 minutes |
Randomisation | No in person visit - Study medication posted | |
3 months | Phone call check in with study coordinator | 10-15 minutes |
6 months | Phone call check in with study coordinator New study medication posted | 1-2 hours |
12 months | Health check-up:
| 1-2 hours |
The above study schedule, from 3 months will repeat for the duration of participation (typically 3.5 - 4 years).
How to participate
Participant Information Flyer and Consent Forms
Register your interest in participating in this study.